NCT03897075已完成3 期
A Multicenter, Randomized, Double-Blind, Placebo-Controlled Clinical Study to Assess the Efficacy and Safety of Tildrakizumab in the Treatment of Moderate to Severe Nail Psoriasis
适应症
干预措施
相关药物
试验速览
- 阶段
- 3 期
- 状态
- 已完成
- 入组人数
- 99
- 试验地点
- 17
- 主要终点
- The Proportion of Subjects Who Achieve at Least a 75% Improvement From Baseline in Total mNAPSI at Week 28.
研究概览
简要总结
Phase 3b study to Assess the Efficacy and Safety of Tildrakizumab in the Treatment of Moderate to Severe Nail Psoriasis
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Double (Participant, Investigator)
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Subjects are eligible to be included in the study only if all of the following criteria apply:
- •Subjects with a chronic moderate to severe plaque-type psoriasis for at least 6 months (as determined by subject interview and confirmation of diagnosis through physical examination by Investigator).
- •Subjects must have moderate to severe nail psoriasis at Screening and Baseline, defined by:
- •mNAPSI score of ≥
- •ViSENPsO ≥3
- •Subjects must have moderate to severe plaque psoriasis at Screening and Baseline, defined by:
- •s-PGA score of at least
- •Body Surface Area (BSA) involvement of ≥10%.
- •Subjects must be considered candidates for systemic therapy, meaning psoriasis inadequately controlled by topical treatments (corticosteroids), and/or phototherapy, and/or previous systemic therapy.
排除标准
- •Subjects are excluded from the study if any of the following criteria apply:
- •Subjects who have predominantly non-plaque forms of psoriasis, specifically erythrodermic psoriasis, predominantly pustular psoriasis, medication-induced, or medication-exacerbated psoriasis, or new-onset guttate psoriasis.
- •Subjects with ongoing inflammatory skin diseases other than psoriasis or any other disease affecting the fingernails, which may potentially confound the evaluation of study treatment.
- •Subjects with fungal nail infection should be excluded from the study. Subjects in whom the Investigator suspects a fungal nail infection in addition to nail psoriasis should have scrapings sent for direct microscopy and fungal culture. If fungal culture or direct microscopy of nail scrapings turns out to be positive for fungal infection, the subject should be excluded from the study. At the discretion of the investigator, Periodic Acid-Schiff (PAS) staining for nail clippings could also be considered to rule of fungal infection of the nails. Direct microscopy or fungal culture are not required if fungal infection is diagnosed in PAS staining.
- •Subjects with any previous use of tildrakizumab or other IL-23/Th-17 pathway inhibitors, including p40, p19 and IL-17 antagonists for psoriasis.
- •Subjects with known history of allergy or hypersensitivity to any of the inactive ingredients of the Tildrakizumab or placebo formulations.
研究组 & 干预措施
Arm A
Experimental
干预措施: Tildrakizumab (Drug)
Arm B
Placebo Comparator
干预措施: Tildrakizumab (Drug)
Arm B
Placebo Comparator
干预措施: Placebo (Drug)
结局指标
主要结局
The Proportion of Subjects Who Achieve at Least a 75% Improvement From Baseline in Total mNAPSI at Week 28.
时间窗: Week 28
Primary Efficacy Endpoint
次要结局
- The Proportion of Subjects With a Score of "0 - Normal" or "1 - Minimal Nail Psoriasis" and at Least a 2-point Decrease From Baseline at Week 28 as Measured by the ViSENPsO.(Week 28)
- The Proportion of Subjects With at Least 3 Point Decrease From Baseline, in Nail Pain NRS Score in Subjects With Baseline Nail Pain NRS Score of >3(Week 28)
研究者
研究点 (17)
Loading locations...
相似试验
进行中（未招募）
3 期
A Study to Evaluate the Efficacy and Safety of Subcutaneous Tildrakizumab in Subjects With Moderate to Severe Genital Psoriasis.Moderate to Severe Genital PsoriasisNCT06611163Sun Pharmaceutical Industries Limited206
已完成
3 期
A Study to Evaluate the Efficacy and Safety/Tolerability of Subcutaneous Tildrakizumab (SCH 900222/MK-3222) in Participants With Moderate-to-Severe Chronic Plaque Psoriasis Followed by a Long-term Extension Study (MK-3222-011)Plaque PsoriasisNCT01729754Sun Pharmaceutical Industries Limited1,090
已完成
3 期
A Study With a Initial Treatment Period Followed by a Randomized-withdrawal Period to Evaluate the Efficacy and Safety of Bimekizumab in Adult Subjects With Moderate to Severe Chronic Plaque PsoriasisChronic Plaque PsoriasisModerate to Severe Chronic Plaque PsoriasisPsoriatic ArthritisNCT03410992UCB Biopharma SRL435
已完成
3 期
An Induction Study of Mirikizumab in Participants With Moderately to Severely Active Ulcerative Colitis (LUCENT 1)Ulcerative ColitisNCT03518086Eli Lilly and Company1,281
已完成
3 期
A Study of the Efficacy and Safety of Tocilizumab in Participants With Systemic Sclerosis (SSc)Systemic SclerosisNCT02453256Hoffmann-La Roche212